These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 24087965)

  • 21. NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View.
    Angoulvant D; Sabouret P; Savage MP
    Am J Cardiovasc Drugs; 2021 Sep; 21(5):483-486. PubMed ID: 33674980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ticagrelor: the first novel reversible P2Y(12) inhibitor.
    Htun WW; Steinhubl SR
    Expert Opin Pharmacother; 2013 Feb; 14(2):237-45. PubMed ID: 23268703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations.
    Jukema JW; Lettino M; Widimský P; Danchin N; Bardaji A; Barrabes JA; Cequier A; Claeys MJ; De Luca L; Dörler J; Erlinge D; Erne P; Goldstein P; Koul SM; Lemesle G; Lüscher TF; Matter CM; Montalescot G; Radovanovic D; Lopez-Sendón J; Tousek P; Weidinger F; Weston CF; Zaman A; Zeymer U;
    Eur Heart J Cardiovasc Pharmacother; 2015 Oct; 1(4):232-44. PubMed ID: 27532447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing the acute coronary syndrome patient: Evidence based recommendations for anti-platelet therapy.
    Clark MG; Beavers C; Osborne J
    Heart Lung; 2015; 44(2):141-9. PubMed ID: 25592204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
    Spinler SA; Hilleman DE; Cheng JW; Howard PA; Mauro VF; Lopez LM; Munger MA; Gardner SF; Nappi JM
    Ann Pharmacother; 2001 May; 35(5):589-617. PubMed ID: 11346067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.
    Cheng JW
    Clin Ther; 2012 Jun; 34(6):1209-20. PubMed ID: 22521881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The European Society of Cardiology (ESC) guidelines for percutaneous coronary interventions (PCI). Three case reports].
    Silber S; Richartz BM; Brilmayer M;
    Herz; 2006 Dec; 31(9):836-46, 848. PubMed ID: 17180646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015?
    Qutub MA; Chong AY; So DY
    Can J Cardiol; 2015 Dec; 31(12):1481-4. PubMed ID: 26243350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New ESC guidelines for the management of acute coronary syndromes - updated national guidelines are called for].
    Brandberg H; Jernberg T
    Lakartidningen; 2021 Jan; 118():. PubMed ID: 33474719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts' standpoint.
    Kubica J; Adamski P; Paciorek P; Ładny JR; Kalarus Z; Banasiak W; Kochman W; Gorący J; Wożakowska-Kapłon B; Navarese EP; Kleinrok A; Gil R; Lesiak M; Drożdż J; Kubica A; Filipiak KJ; Kaźmierczak J; Goch A; Grajek S; Basiński A; Szarpak Ł; Grześk G; Hoffman P; Wojakowski W; Gąsior Z; Dobrzycki S; Siller-Matula JM; Witkowski A; Kuliczkowski W; Gruchała M; Timler D; Opolski G; Dudek D; Legutko J; Zielińska M; Wójcik J
    Cardiol J; 2018; 25(3):291-300. PubMed ID: 29671864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.
    Bavishi C; Panwar S; Messerli FH; Bangalore S
    Am J Cardiol; 2015 Sep; 116(5):809-17. PubMed ID: 26119655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients: cost-effectiveness analyses for six European perspectives.
    Coleman CI; Limone BL
    Thromb Haemost; 2014 Jan; 111(1):103-10. PubMed ID: 24136466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ticagrelor: a review of its use in adults with acute coronary syndromes.
    Dhillon S
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):51-68. PubMed ID: 25672642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome.
    Piccolo R; Di Gioia G; Niglio T; D'Anna C; De Rosa R; Strisciuglio T; Bevilacqua M; Piscione F; Cirillo P; Galasso G
    Angiology; 2014 Feb; 65(2):130-6. PubMed ID: 23221279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study.
    De Luca L; Leonardi S; Cavallini C; Lucci D; Musumeci G; Caporale R; Abrignani MG; Lupi A; Rakar S; Gulizia MM; Bovenzi FM; De Servi S;
    Eur Heart J Acute Cardiovasc Care; 2015 Oct; 4(5):441-52. PubMed ID: 25414322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the American College of Cardiology/American Heart Association and the European Society of Cardiology Guidelines for the Management of Patients With Valvular Heart Disease.
    Alame AJ; Karatasakis A; Karacsonyi J; Danek BA; Sorajja P; Gössl M; Garcia S; Jneid H; Kakouros N; Martinez-Parachini JR; Resendes E; Kalsaria P; Roesle M; Rangan BV; Banerjee S; Brilakis ES
    J Invasive Cardiol; 2017 Sep; 29(9):320-326. PubMed ID: 28420803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
    Husted S
    Postgrad Med; 2011 Nov; 123(6):79-90. PubMed ID: 22104457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.